Screening for Prostate Cancer: A Review of the ERSPC and PLCO Trials.

摘要: The advent of prostate-specific antigen (PSA) testing in the early 1980s revolutionized diagnosis prostate cancer. As a result PSA testing, there has been surge number cancer diagnoses. This review examines results 2 recent landmark trials that studied effect screening on mortality: European Randomized Study Screening for Prostate Cancer (ERSPC) and US-based Prostate, Lung, Colorectal, Ovarian (PLCO) Trial.